Jump to content

Dalzanemdor

From Wikipedia, the free encyclopedia
(Redirected from SAGE-718)
Dalzanemdor
Clinical data
Other namesSAGE-718
Legal status
Legal status
  • Investigational
Identifiers
  • (3S,8R,9S,10R,13R,14S,17R)-3,13-Dimethyl-17-[(2R,5S)-6,6,6-trifluoro-5-hydroxy-5-methylhexan-2-yl]-2,4,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
CAS Number
PubChem CID
KEGG
ChEMBL
Chemical and physical data
FormulaC26H41F3O2
Molar mass442.607 g·mol−1
3D model (JSmol)
  • C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@H]3CC[C@](C4)(C)O)C
  • InChI=InChI=1S/C26H41F3O2/c1-16(9-14-25(4,31)26(27,28)29)21-7-8-22-20-6-5-17-15-23(2,30)12-10-18(17)19(20)11-13-24(21,22)3/h5,16,18-22,30-31H,6-15H2,1-4H3/t16-,18+,19-,20-,21-,22+,23+,24-,25+/m1/s1
  • Key:RTBRKGVJBGKMFF-YMEFNWBESA-N

Dalzanemdor (INNTooltip International Nonproprietary Name;[1] development code SAGE-718) is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment.[2] It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition.[3] Dalzanemdor is an analogue of the neurosteroid 24S-hydroxycholesterol.[3]

As of 2022, dalzanemdor is in Phase II clinical trials[3] for Alzheimer's disease,[4][5][6] Parkinson's disease, and Huntington's disease.[7][8]

References

[edit]
  1. ^ "Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor". Sage Therapeutics. December 5, 2023.
  2. ^ Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. (July 2022). "SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment". Journal of Medicinal Chemistry. 65 (13): 9063–9075. doi:10.1021/acs.jmedchem.2c00313. PMID 35785990. S2CID 250250073.
  3. ^ a b c "SAGE-718". ALZFORUM.
  4. ^ Shapiro L (5 April 2022). "#AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's". BioNews, Inc.
  5. ^ "SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study" (PDF). American Academy of Neurology (AAN) 74th Annual Meeting Abstract.
  6. ^ Castañeda R (16 November 2021). "Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion". Clinical Trials Arena. Archived from the original on 28 May 2022. Retrieved 13 July 2022.
  7. ^ "Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718". Huntington's Disease Society of America. 22 February 2022.
  8. ^ Wexler M (21 September 2021). "SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy". BioNews, Inc.
[edit]


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Dalzanemdor&oldid=1244778609"